Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Not to be sneezed at - Allergy Therapeutics revenues up 18%

The company, which has developed short course inoculations against hay fever, said turnover was £40.4mln in the six months ended December 31.
Not to be sneezed at - Allergy Therapeutics revenues up 18%
As the name suggests, the company has developed drugs that protect against common allergies

Allergy Therapeutics plc (LON:AGY) said it had gained share in a “flat” European market as it said sales had grown strongly in the first half of its financial year.

The company, which has developed short course inoculations against hay fever, said turnover was £40.4mln in the six months ended December 31.

That represents an increase of 18% at constant currencies or 39% when the translational currency effect of the weak pound is brought into play.

“We are excited by the prospects of the company as we continue expanding our operations in Europe, progressing our development pipeline and moving forward with a world-class portfolio of allergy vaccines,” said chief executive Manuel Llobet.

“We are confident about the full year and look forward to updating shareholders on further progress throughout 2017."

The drug development programme in the US and Europe is proceeding to plan, Allergy said.

View full AGY profile View Profile

Allergy Therapeutics plc Timeline

Related Articles

newspaper with word cancer magnified
July 11 2017
"In our view, the potential for SCIB1 [Scancell's skin cancer treatment], as already demonstrated by the survival data, is remarkable," said one broker recently
Lab technician
August 07 2017
Avacta said it has developed multiple PD-L1 inhibitors, which are designed to use the body's own immune system to battle cancer
Cancer highlighted
July 10 2017
The collaboration will see PDS Biotechnology Corp and a subsidiary of Merck & Co Inc embark on a new clinical trial collaboration for metastatic head and neck cancer

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use